Last Update 02 Jul 26
Fair value Decreased 40%6855: Late Stage Hematology Trials And BTK Degrader Will Drive Future Upside
Analysts have adjusted their fair value estimate for Ascentage Pharma Group International from HK$72.45 to HK$43.67, reflecting updated assumptions on discount rate, revenue growth, profit margins, and future P/E after recent coverage initiations that highlight approved drugs in China, multiple FDA-cleared Phase 3 trials, and plans for a BTK degrader entering Phase 1 in 2026.
Analyst Commentary
Recent Street research on Ascentage Pharma Group International points to a mix of optimism about the company’s approved drugs in China and its expanding late stage pipeline, together with a more restrained stance on how quickly that pipeline might translate into financial outcomes. Analysts have highlighted the two commercial products in China and the multiple FDA cleared Phase 3 trials as key drivers, while also drawing attention to the valuation assumptions and execution milestones that need to be met for those assets to fully support current fair value estimates.
Several reports reference the planned BTK degrader entering Phase 1 in 2026 as an important proof point for Ascentage Pharma’s broader scientific platform. At the same time, the timing and cost of progressing early stage assets, alongside the requirements for global registration and commercialization of the existing drugs, are raised as variables that could influence how investors assess the stock over the medium term.
Across the coverage, there is a clear focus on how the updated fair value estimate of HK$43.67 compares with other published price targets, including the US$45 target cited in one recent initiation. This spread between targets, even if relatively tight, reflects different views on discount rates, long term revenue trajectories, achievable profit margins, and the P/E multiples that might be applied if key development and commercialization steps are successful.
Analysts also highlight that Ascentage Pharma’s concentration in oncology and hematology, while core to its identity, exposes the company to the usual sector specific risks around clinical trial outcomes, regulatory decisions, and competitive products in the same indications. The bar for late stage oncology drugs is high, and any change in trial timelines or study designs could affect how quickly revenue from new indications might build relative to current expectations.
For investors following Ascentage Pharma Group International, the common thread across recent commentary is that the story is closely tied to execution on the existing Phase 3 programs and the successful start of the BTK degrader trial. As those milestones play out, analysts are likely to revisit both fair value estimates and broader assumptions on the company’s ability to convert its pipeline into sustainable cash flows.
Bearish Takeaways
- Bearish analysts point to the reset in fair value from HK$72.45 to HK$43.67 as a sign that earlier assumptions on discount rate, revenue growth, margins, and future P/E may have been too optimistic, which in their view leaves less room for disappointment on execution.
- Cautious commentary focuses on the gap between the HK$43.67 fair value estimate and the US$45 price target referenced in Street research, arguing that small differences in trial success rates or commercialization pace could justify further adjustments to valuation.
- Some bearish analysts flag the reliance on two currently approved drugs and a set of ongoing Phase 3 trials as a concentration risk, warning that any delay or weaker than expected uptake in new indications could strain the growth assumptions embedded in current forecasts.
- There is concern that the BTK degrader, which is expected to enter Phase 1 in 2026, adds another layer of development and funding requirements, and bearish analysts see this as increasing execution risk at a time when valuation assumptions have already been tightened.
What’s in the News for Ascentage Pharma Group International
- Seventeen clinical updates on core assets, including eight posters, were presented at the EHA2026 Congress, with new data on olverembatinib in multiple CML and Ph+ ALL settings and on lisaftoclax in CLL/SLL and myeloid neoplasms, highlighting breadth of late stage hematology workstreams. (Source: EHA2026 clinical updates)
- Updated efficacy and safety data for olverembatinib as a second line therapy in CML CP were featured in a rapid oral session at the 2026 ASCO Annual Meeting. Long term follow up was cited as supporting its role for patients who have failed first line TKI therapy in China and ongoing global Phase 3 programs in CML, Ph+ ALL and SDH deficient GIST. (Source: ASCO 2026 olverembatinib update)
- Ascentage Pharma Group International reported first pediatric data for alrizomadlin, an MDM2 p53 inhibitor, alone and with lisaftoclax in relapsed or metastatic rhabdomyosarcoma and other soft tissue sarcomas, with early antitumor activity and inclusion of alrizomadlin in China’s SPARK Plan for pediatric solid tumors. (Source: ASCO 62nd Annual Meeting pediatric trial)
- Multiple abstracts across olverembatinib, lisaftoclax and alrizomadlin were accepted for rapid oral and poster presentations at the 2026 ASCO Meeting, including trials in CML, Ph+ ALL, SDH deficient tumors and CLL/SLL, signaling continued clinical execution across hematology and select solid tumor indications. (Source: ASCO 2026 abstract selections)
- Shareholders approved a new amended and restated memorandum and articles of association at the May 20, 2026 AGM, following prior proposals to revise company constitutional documents. (Source: AGM bylaws amendments)
Valuation Changes for Ascentage Pharma Group International
- Fair Value: reset from HK$72.45 to HK$43.67, a substantial reduction that tightens the implied upside built into the model.
- Discount Rate: adjusted slightly higher from 7.48% to 7.58%, signaling a modestly higher required return on Ascentage Pharma Group International.
- CN¥ Revenue Growth: refined from 27.52% to 27.97%, a small upward tweak to projected top line expansion in the updated assumptions.
- CN¥ Profit Margin: held broadly stable at about 17.13%, with only a minimal change in the modeled long term earnings profile.
- Future P/E: reduced from 172.68x to 103.73x, indicating a meaningfully lower valuation multiple applied to potential future earnings.
Key Takeaways
- Over-reliance on non-recurring partnership payments and pipeline-stage products renders future revenue and earnings highly uncertain amidst rising competition and healthcare cost pressures.
- Intensifying regulatory, geopolitical, and funding challenges threaten global expansion, product launches, and long-term financial sustainability, exposing the company to dilution and operational cutbacks.
- Expanding product sales, global partnerships, robust late-stage pipeline, clinical differentiation, and financial strength position the company for sustained growth, higher margins, and reduced risk.
Catalysts
About Ascentage Pharma Group International- A clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China.
- Revenue and earnings are heavily inflated by one-off option and equity payments from the Takeda partnership, masking the company's underlying dependence on partnership capital rather than sustainable sales growth, which will lead to declining reported revenue and weaker profit margins once these non-recurring payments are exhausted.
- With escalating pressure from global healthcare cost containment, including new price controls and expanded reimbursement programs like China's NRDL, there is likely to be severe downward pressure on net pricing for Olverembatinib and Lisaftoclax, which will significantly restrict future revenue growth even as sales volumes rise.
- As geopolitical tensions and deglobalization intensify, Ascentage's ability to access Western markets for both clinical trials and commercial products is at risk, threatening regulatory approvals, cross-border deals, and the viability of global expansion efforts that support long-term top-line and earnings growth.
- The company remains fundamentally vulnerable due to its heavy reliance on a development-stage pipeline in highly competitive oncology segments, where clinical failure or regulatory delay-compounded by industry-wide scrutiny of trial design-could halt new product launches and trigger significant drops in projected revenue and net margins.
- Persistent high R&D spending, combined with a tightening global funding environment and the specter of rising interest rates, makes Ascentage increasingly exposed to future shareholder dilution, cost-cutting, or operational retrenchment, all of which would suppress earnings and limit the potential for positive cash flow over the long term.
Ascentage Pharma Group International Future Earnings and Revenue Growth
Assumptions
How have these above catalysts been quantified?
- This narrative explores a more pessimistic perspective on Ascentage Pharma Group International compared to the consensus, based on a Fair Value that aligns with the bearish cohort of analysts.
- The bearish analysts are assuming Ascentage Pharma Group International's revenue will grow by 28.0% annually over the next 3 years.
- The bearish analysts are not forecasting that Ascentage Pharma Group International will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Ascentage Pharma Group International's profit margin will increase from -216.5% to the average HK Biotechs industry of 17.1% in 3 years.
- If Ascentage Pharma Group International's profit margin were to converge on the industry average, you could expect earnings to reach CN¥206.1 million (and earnings per share of CN¥0.45) by about July 2029, up from -CN¥1.2 billion today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting CN¥5.2 billion in earnings, and the most bearish expecting CN¥-2.4 billion.
- In order for the above numbers to justify the price target of the more bearish analyst cohort, the company would need to trade at a PE ratio of 103.7x on those 2029 earnings, up from -8.5x today. This future PE is greater than the current PE for the HK Biotechs industry at 18.0x.
- The bearish analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
- To value all of this in today's terms, we will use a discount rate of 7.58%, as per the Simply Wall St company report.
Risks
What could happen that would invalidate this narrative?- The rapid growth in Olverembatinib sales, especially following China NRDL inclusion and label expansion, signals expanding addressable markets and potential for sustained revenue growth in China, which could positively impact top line and operating earnings.
- The execution of a global partnership with Takeda, featuring significant upfront and potential milestone payments as well as double-digit royalties on ex-China sales, provides validation of the lead asset and de-risks international commercialization, supporting higher near-term and long-term cash flow and margin stability.
- The company's expanding late-stage pipeline, with multiple Phase III global registration trials for both Olverembatinib and Lisaftoclax and several additional innovative compounds advancing, increases the likelihood of future product launches and diversified revenue streams, improving long-term revenue and potentially boosting net margins.
- Advancements in clinical differentiation of lead compounds-for example, the convenience and tolerability of Lisaftoclax's dosing regimen compared to competitors and Olverembatinib's efficacy in resistant mutations-enhance competitive positioning, which can contribute to premium pricing and improved gross margins.
- Strong balance sheet bolstered by a recent NASDAQ IPO, substantial existing cash reserves, and anticipated inflows from commercial sales and partnership milestones reduces near-term dilution risk and enables continued R&D investment, thus increasing the company's ability to sustain growth and ultimately transition to net profitability.
Valuation
How have all the factors above been brought together to estimate a fair value?
- The assumed bearish price target for Ascentage Pharma Group International is HK$43.67, which represents up to two standard deviations below the consensus price target of HK$87.18. This valuation is based on what can be assumed as the expectations of Ascentage Pharma Group International's future earnings growth, profit margins and other risk factors from analysts on the more bearish end of the spectrum.
- However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of HK$113.9, and the most bearish reporting a price target of just HK$43.67.
- In order for you to agree with the more bearish analyst cohort, you'd need to believe that by 2029, revenues will be CN¥1.2 billion, earnings will come to CN¥206.1 million, and it would be trading on a PE ratio of 103.7x, assuming you use a discount rate of 7.6%.
- Given the current share price of HK$33.2, the analyst price target of HK$43.67 is 24.0% higher.
- We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.
Have other thoughts on Ascentage Pharma Group International?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeHow well do narratives help inform your perspective?
Disclaimer
AnalystLowTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystLowTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystLowTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.
